Efficacy and Safety of Guihuang Formula in Treating Type Ⅲ Prostatitis Patients with Dampness-Heat and Blood Stasis Syndrome: A Randomized Controlled Trial

作     者：LIU Sheng-jing DENG Ying-jun ZENG Yin ZHAO Ming GUO Jun GAO Qing-he LIU Sheng-jing;DENG Ying-jun;ZENG Yin;ZHAO Ming;GUO Jun;GAO Qing-he

作者机构：Department of AndrologyXiyuan Hospital of China Academy of Chinese Medical SciencesBeijing(100091)China Graduate School of China Academy of Chinese Medical SciencesBeijing(100700)China Department of AndrologyBeijing Chinese Medicine Hospital Affiliated to Capital Medical UniversityBeijing(100010)China Graduate SchoolBeijing University of Chinese MedicineBeijing(100029)China 

出 版 物：《Chinese Journal of Integrative Medicine》 (中国结合医学杂志（英文版）)

年 卷 期：2022年第28卷第10期

页      面：879-884页

核心收录：

学科分类：1006[医学-中西医结合] 1002[医学-临床医学] 10[医学] 100602[医学-中西医结合临床] 

基　　金：Supported by the National Natural Science Foundation of China (No.82104880) Scientific and Technological Innovation Project of China Academy of Chinese Medical Sciences (No.CI2021A02208) the Nursery Project of Xiyuan Hospital of China Academy of Chinese Medical Sciences (No.2019XYMP-23)。 

主　　题：typeⅢprostatitis dampness-heat and blood stasis syndrome Guihuang Formula Chinese medicine randomized controlled trial 

摘      要：Objective: To observe the efficacy and safety of Guihuang Formula(GHF) in treating patients with type Ⅲ prostatitis and Chinese medicine syndrome of dampness-heat and blood stasis. Methods: Sixty-six type Ⅲ prostatitis patients with dampness-heat and blood stasis syndrome were randomly divided into the treatment group(GHF) and the control group(tamsulosin) using a random number table, with 33 cases each group. The treatment group received GHF twice a day, and the control group received tamsulosin 0.2 mg once daily before bedtime. Patients in both groups received treatment for 6 weeks and was followed up for 2 weeks. The outcomes included the National Institute of Health Chronic Prostatitis Symptom Index(NIH-CPSI) score, Chinese Medicine Symptoms Score(CMSS), expressed prostatic secretions(EPS) and adverse events(AEs). Results: After treatment, the NIH-CPSI total score and domain scores of pain discomfort, urination and quality of life decreased significantly from the baseline in both groups(P0.05). In addition, no serious AEs were observed. Conclusion: GHF is effective in treating type Ⅲ prostatitis patients with dampness-heat and blood stasis syndrome without serious AEs.(Registration No. ChiCTR1900026966)